

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

NCI-H226

RRID:CVCL_1544

Type: Cell Line

Proper Citation

RRID:CVCL_1544

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1544

Proper Citation: RRID:CVCL_1544

Description: Cell line NCI-H226 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pleural epithelioid mesothelioma

Defining Citation: [PMID:1311061](#), [PMID:1568228](#), [PMID:2041050](#), [PMID:2386953](#), [PMID:3335022](#), [PMID:6272398](#), [PMID:8806092](#), [PMID:8806101](#), [PMID:8956792](#), [PMID:9331090](#), [PMID:9488600](#), [PMID:9649128](#), [PMID:10700174](#), [PMID:11030152](#), [PMID:11369051](#), [PMID:15748285](#), [PMID:16187286](#), [PMID:17088437](#), [PMID:17332333](#), [PMID:17458138](#), [PMID:18083107](#), [PMID:19372543](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22961666](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24002593](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25902174](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:29718670](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Caution: Indicated to have a TP53 p.Arg158Leu (c.473G>T) mutation according to PubMed=1311061, but no TP53 mutation detected according to PubMed=20557307, CCLE and Cosmic-CLP., Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H226

Synonyms: NCI.H226, NCI H226, H226, H-226, HUT-226, HUT 226, NCIH226

Cross References: BTO:BTO_0003008, CLO:CLO_0008068, EFO:EFO_0002285, AddexBio:C0016011/4916, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5826, BioGRID_ORCS_Cell_line:960, BioSample:SAMN03471987, BioSample:SAMN10987668, cancercellines:CVCL_1544, CCRID:3101HUMTCHu235, CCRID:4201HUM-CCTCC00634, Cell_Model_Passport:SIDM00139, ChEMBL-Cells:ChEMBL3307697, ChEMBL-Targets:ChEMBL614740, CLS:305091, Cosmic:733816, Cosmic:875850, Cosmic:877259, Cosmic:877402, Cosmic:886388, Cosmic:903570, Cosmic:905941, Cosmic:931374, Cosmic:974291, Cosmic:980961, Cosmic:1006539, Cosmic:1028953, Cosmic:1032433, Cosmic:1047100, Cosmic:1092618, Cosmic:1152497, Cosmic:1175863, Cosmic:1188585, Cosmic:1219111, Cosmic:1239951, Cosmic:1305346, Cosmic:1312331, Cosmic:1436011, Cosmic:1481544, Cosmic:1802319, Cosmic:1870270, Cosmic:1963326, Cosmic:1995565, Cosmic:1998460, Cosmic:2060522, Cosmic:2560228, Cosmic:2664122, Cosmic:2772152, Cosmic-CLP:905941, DepMap:ACH-000367, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS328RVB, ENCODE:ENCBS986NWY, FANTOM5_SSTAR:10846-111E9, GDSC:905941, GEO:GSM2123, GEO:GSM50213, GEO:GSM50276, GEO:GSM62965, GEO:GSM206486, GEO:GSM274785, GEO:GSM274821, GEO:GSM743452, GEO:GSM750820, GEO:GSM794278, GEO:GSM799340, GEO:GSM799403, GEO:GSM844640, GEO:GSM844641, GEO:GSM844642, GEO:GSM847074, GEO:GSM887416, GEO:GSM888495, GEO:GSM1153411, GEO:GSM1178441, GEO:GSM1178442, GEO:GSM1178443, GEO:GSM1181351, GEO:GSM1374728, GEO:GSM1374729, GEO:GSM1374730, GEO:GSM1670227, GEO:GSM2124673, IARC_TP53:515, IARC_TP53:21406, IARC_TP53:23624, IGRhCellID:NCIH226, KCLB:90226, LiGeA:CCLE_131, LINCSPDP:LCL-1597, Lonza:839, NCI-DTP:NCI-H226, PharmacDB:NCIH226_1082_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1544, PubChem_Cell_line:CVCL_1544, SKY/M-FISH/CGH:2802, Wikidata:Q54907948

ID: CVCL_1544

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260829T234732+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H226.

Warning: Discontinued: KCLB; 90226

Caution: Indicated to have a TP53 p.Arg158Leu (c.473G>T) mutation according to PubMed=1311061, but no TP53 mutation detected according to PubMed=20557307, CCLE and Cosmic-CLP., Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer

cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 430 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.

Zhang X, et al. (2026) Do G4 ligands induce mitochondrial dysfunction without ROS induction. *iScience*, 29(6), 116036.

Izzo LT, et al. (2026) KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma. *Cancer research*.

Hamada M, et al. (2026) Biotin binder (BB) and BB-LucYY5: A sensitive and quantitative platform for biotin-labelled protein analysis. *Biochemical and biophysical research communications*, 796, 153125.

Xu HW, et al. (2026) GM-CSF Armed Oncolytic Adenovirus Enhances T-Cell Infiltration and Suppresses Local and Distal Tumor Growth. *Viruses*, 18(1).

Sueyoshi K, et al. (2026) Cooperative response loops enhanced by histamine signaling during tumor-neutrophil crosstalk in pleural mesothelioma. *Cell reports*, 45(5), 117361.

Carpentier J, et al. (2025) Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma. *iScience*, 28(1), 111525.

Champagne J, et al. (2025) Adoptive T??cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Sun Y, et al. (2025) Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e08754.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Zheng J, et al. (2025) DACT3-DVL1 Interaction-Mediated Canonical WNT Signaling Regulates Non-Small Cell Lung Cancer Progression and Cisplatin Resistance. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(16), e70975.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. *Molecular cell*.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. *Cell reports*, 44(6), 115722.

Bratt AS, et al. (2025) Pharmacologic interrogation of USP28 cellular function in p53 signaling. *Cell chemical biology*.

Wang X, et al. (2025) HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. *BMC cancer*, 25(1), 1317.

Kahlhofer J, et al. (2025) TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence. *The EMBO journal*, 44(23), 7119.

Jiang Y, et al. (2025) USP8 deubiquitylation-boosted NSUN4 potentiates lung squamous cell carcinoma progression by m5C methylation of DHCR24. *Cell reports*, 44(8), 116158.

Wei X, et al. (2025) Tumor cell-intrinsic circular RNA circFNDC3B attenuates CD8⁺ T cells infiltration in non-small cell lung cancer. *Communications biology*, 8(1), 711.

Kouro T, et al. (2024) Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. *International journal of cancer*, 154(10), 1828.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T⁺ cells. *Cell reports. Medicine*, 5(11), 101827.